Profile
CPHI ZTS TAK HLN TEVA NBIX
Company Name China Pharma Holdings, Inc. Zoetis Inc. Takeda Pharmaceutical Company Limited Haleon plc Teva Pharmaceutical Industries Limited Neurocrine Biosciences, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $4.86M $79.42B $41.48B $38.86B $18.26B $14.32B
Employees 0.23K 14.10K 49.10K 25.41K 35.00K 1.45K
CEO Ms. Zhilin Li Ms. Kristin C. Peck Mr. Christophe Weber Mr. Brian James McNamara Mr. Richard D. Francis Dr. Kevin C. Gorman Ph.D.
Ratings
CPHI ZTS TAK HLN TEVA NBIX
Quant Rating Score 2 5 3 4 3 5
Quant Rating Sell Strong Buy Neutral Buy Neutral Strong Buy
Trading
CPHI ZTS TAK HLN TEVA NBIX
Last Close $0.3279 $174.06 $13.22 $8.51 $16.29 $142.29
High 52 $0.43 $200.09 $16.42 $8.95 $17.09 $143.19
Low 52 $0.07 $145.54 $13.03 $7.78 $7.2 $89.53
Price vs. 52 Week High -23.74 % -13.01 % -19.49 % -4.92 % -4.68 % -0.63 %
Price vs. 52 Week Low 368.43 % 19.6 % 1.46 % 9.38 % 126.25 % 58.93 %
Total Return
CPHI ZTS TAK HLN TEVA NBIX
1 Month Return 0.06 % 13.68 % 0.46 % 4.67 % 27.46 % 7.36 %
3 Month Return 218.35 % -7.61 % -9.58 % 3.53 % 25.12 % 7.54 %
6 Month Return 265.96 % -0.42 % -5.23 % 3.15 % 80 % 30.61 %
9 Month Return 49.73 % -4.14 % -12.16 % 3.4 % 70.4 % 33.03 %
YTD Return 170.99 % -11.81 % -7.36 % 3.4 % 56.03 % 7.99 %
1 Year Return 6.84 % -3.15 % -17.68 % 0.41 % 97.22 % 49.98 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
CPHI ZTS TAK HLN TEVA NBIX
Dividend Yield Percentage (TTM) - 0.93 % 4.25 % 2.27 % - -
Dividend Paid and Capex Coverage Ration (TTM) 40.51 % 1.76 % 0.92 % - 3.3 % 20.82 %
Dividend Per Share (TTM) - 1.61 % 0.56 % 0.15 % - -
Payout Ratio (TTM) - 29.95 % 199.34 % - - -
Growth
CPHI ZTS TAK HLN TEVA NBIX
Asset Growth -7.39 % -4.28 % 5.92 % -2.18 % -1.2 % 37.27 %
Gross Profit Growth -2.22 % 3.7 % 13.05 % 5.85 % 9.64 % 26.06 %
Revenue Growth -13.48 % 5.74 % 12.85 % 4.09 % 6.16 % 26.76 %
Revenue 3 Year -83.36 % 31.98 % 22.8 % 13.9 % -6.92 % 71.93 %
Revenue 5 Year -26.77 % 53.64 % 128.91 % 32.87 % -23.33 % 308.36 %
Revenue 10 Year -72.53 % 103.1 % 163.14 % 32.87 % -40.82 % 44100.16 %
EBIT Growth 22.46 % 6.27 % 6.44 % 37.26 % -84.52 % 0.76 %
Net Income Growth 69.88 % 10.88 % 37.8 % -1.04 % 76.24 % 61.62 %
Net Income 3 Yeari Growth Per Share 74.88 % 47.55 % 619.06 % -8.67 % 86.29 % -41.58 %
Net Income 5 Yeari Growth Per Share 63.11 % 71.94 % 70.7 % 59.66 % 76.28 % 1054.95 %
Net Income 10 Yeari Growth Per Share 80.22 % 404.24 % 145.77 % 59.66 % -133.42 % 470.4 %
Operating Income Growth 22.46 % 6.27 % 6.44 % 37.26 % -84.52 % 0.76 %
Operating Cash Flow Growth (CFG) -70.84 % 23.06 % -13 % -16.48 % -13.96 % 14.88 %
Operating 3 Year CFG -326.92 % 14.12 % 46.41 % 22.08 % 10.09 % 62.6 %
Operating 5 Year CFG -171.69 % 37.69 % 160.24 % 118.54 % -48.98 % 275.6 %
Operating 10 Year CFG -110.46 % 274.61 % 223.1 % 118.54 % -67.94 % 1000.37 %
EPS Growth 90.64 % 12.64 % 38.84 % - 76.42 % 59.01 %
EPS Diluted Growth 90.64 % 12.92 % 38.44 % - 76.42 % 58.33 %
Book Value Per Share -46.01 % 15.34 % 12.65 % 1.38 % -5.72 % 28.15 %
Share Holder 3 Year Equity Growth Per Share -75.99 % 36.7 % 34.99 % -36.6 % -26.74 % 88.86 %
Share Holder 5 Year Equity Growth Per Share -68.21 % 139.55 % 220.13 % -39.41 % -53.44 % 353.33 %
Share Holder 10 Year Equity Growth Per Share -92.79 % 476.36 % 199.32 % -39.41 % -74.76 % 1167.34 %
Dividend Per Share Growth - 15.15 % -0.76 % -85.58 % - -
Dividend 3 Year Growth Per Share - 87.76 % -0.78 % -83.69 % - -
Dividend 5 Year Growth Per Share - - 98.17 % -66.42 % - -
Dividend 10 Year Growth Per Share - 665.58 % 100.04 % -66.42 % -100 % -
Debt Growth -47.08 % -15.91 % 0.85 % -9.43 % -6.53 % 62.95 %
Free Cash Flow Growth 12.36 % 22.25 % -63.35 % -20.06 % -19.19 % 11.99 %
Updated On 31 Dec 2023 31 Dec 2023 31 Mar 2023 31 Dec 2023 31 Dec 2023 31 Dec 2023
Profitability
CPHI ZTS TAK HLN TEVA NBIX
Gross Profit Margin TTM -12.64 % 69.2 % 62.16 % 60.04 % 48.99 % 97.78 %
Return on Assets TTM -21.98 % 16.66 % 0.95 % - -1.15 % 10.65 %
Return on Equity TTM -54.31 % 48.41 % 2.06 % 6.53 % -6.86 % 17.45 %
Return on Capital Employed TTM -31.26 % 25.86 % 1.76 % - 3.75 % 17.05 %
Net Income Per EBT TTM 100 % 80.07 % 293.72 % 64.62 % 59.18 % 78.68 %
EBT Per Ebit TTM 108.82 % 92.82 % 21.83 % 82.52 % -76.63 % 99.89 %
EBIT Per Revenue TTM -50.93 % 36.83 % 5.27 % 18.08 % 6.79 % 23.73 %
Cash Flow To Debt Ratio TTM 12.33 % 36.43 % 14.66 % - 8.57 % 118.01 %
Receivables Turnover TTM 17.9 6.75 6.11 - 4.63 4.4
Payables Turnover TTM 11.16 6.64 2.95 - 3.35 0.5
Inventory Turnover TTM 1.97 1.01 1.33 - 2.07 1.18
Fixed Asset Turnover TTM 98.06 % 251.27 % 214.28 % - 267.75 % 572.67 %
Asset Turnover TTM 39.66 % 60.87 % 28.22 % - 37.45 % 57.08 %
Operating Cash Flow Per Share TTM 0.01 5.24 452.81 - 1.5 6.47
Free Cash Flow Per Share TTM 0.01 3.82 146.32 - 1.04 6.16
Cash Per Share TTM 6.39 % 431.22 % 29187.13 % 22.71 % 266.34 % 1213.03 %
Operating Cash Flow Sales Ratio TTM 2.86 % 27.47 % 16.66 % - 10.51 % 32.56 %
Free Cash Flow Operating Cash Flow Ratio TTM 97.53 % 72.95 % 32.31 % - 69.66 % 95.2 %
Cash Flow Coverage Ratios TTM 12.33 % 36.43 % 14.66 % - 8.57 % 118.01 %
Price To Free Cash Flows Ratio TTM 27.17 45.38 28.13 - 15.57 23.31
Price To Operating Cash Flows Ratio TTM 23.48 33.23 4.54 - 10.86 22
Price Cash Flow Ratio TTM 23.48 33.23 4.54 - 10.86 22
Income Statement (TTM)
CPHI ZTS TAK HLN TEVA NBIX
Revenue $0.01B $8.54B $4263.76B $11.3B $15.85B $1.89B
Gross Profit $-0B $5.83B $2184.97B $6.96B $7.65B $1.85B
Gross Profit Ratio -7.2% 68.28% 51.25% 61.6% 48.25% 97.9%
EBITDA $0B $3.56B $1129.23B $2.81B $4.27B $0.42B
Net Income $-0B $2.34B $144.07B $1.05B $-0.56B $0.25B
EPS Diluted -0.91 5.07 91.16 0.11 -0.5 2.47
Balance Sheet (MRQ)
CPHI ZTS TAK HLN TEVA NBIX
Long Term Debt $0B $6.56B $4476.5B $8.8B $18.48B $0.26B
Total Liabilities $0.01B $9.3B $7834.79B $17.33B $35.35B $1.02B
Total Equity $0.01B $4.99B $7274.01B $16.73B $8.13B $2.23B
Total Investments $0B $0.02B $430.61B $0.07B $0.01B $0.94B
Total Debt $0B $6.8B $4843.75B $9.46B $20.15B $0.43B
Total Assets $0.02B $14.29B $15108.79B $34.06B $43.48B $3.25B
Cash Flow Statement (TTM)
CPHI ZTS TAK HLN TEVA NBIX
Net Income $-0B $2.34B $144.07B $1.05B $-0.62B $0.25B
Inventory $-0B $-0.36B $-115.74B $-0.13B $-0.15B $0.01B
Dividends Paid $0B $-0.69B $-287.19B $-0.39B $0B $0B
Operating Cash Flow $-0B $2.35B $640.32B $1.72B $1.37B $0.39B
Capital Expenditure $-0B $-0.73B $-480.73B $-0.34B $-0.53B $-0.03B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 7.38
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 0.3777
AKAN Akanda Corp. 0.1726
ALIM Alimera Sciences, Inc. 3.2
ALVO Alvotech 13.5
ALVOW Alvotech 3.1
AMPH Amphastar Pharmaceuticals, Inc. 43.48
AMRX Amneal Pharmaceuticals, Inc. 6.82
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 61.43
AQST Aquestive Therapeutics, Inc. 3.11
ASRT Assertio Holdings, Inc. 1.07
ATNX Athenex, Inc. 0.2031
AVDL Avadel Pharmaceuticals plc 15.49
AYTU Aytu BioPharma, Inc. 2.94
Unlock